Physicians' Academy for Cardiovascular Education
Member

Type of glycemic control is more important than tight glycemic control

May 1, 2017 - ESC HF 2017, Paris

New diabetes treatments with CV benefit: A changing role for the cardiologist

Apr. 19, 2017 - Robert J Chilton, MD (San Antonio, TX, USA)

Modifying CV risk by managing diabetes

Nov. 12, 2016 - New Orleans, LA, USA - Jorge Plutzky, MD (Boston, MA, USA)

What can new glucose-lowering SGLT2-inhibitors add to CV risk management in diabetes?

Aug. 29, 2016 - ESC Rome, Italy - Prof. Silvio E Inzucchi (New Haven, CT, USA)

HF & Diabetes: SGLT2 inhibition a paradigm shift?

Aug. 29, 2016 - ESC 2016, Rome, Italy - John McMurray, MD University of Glasgow United Kingdom - Recorded at PACE-CME symposium held during ESC 2016 in Rome

Challenging cardiovascular risk in diabetes: ready for a new approach?

Aug. 29, 2016 - John Deanfield, MD, University College London, United Kingdom

Overview of SGLT-2 inhibitors in T2DM management: current position & future promise

Aug. 29, 2016 - ESC, Rome Italy - Silvio Inzucchi, MD, Yale Diabetes Center, New Haven, CT, USA - PACE-CME symposium held at ESC 2016, Rome
##SCROLLER_ITEMS_FULL_TITLE##

The effect of treatment with DPP-4 inhibition on renal complications in diabetic patients.

Aug. 24, 2016 - Bangkok, Thailand - Prof. Per-Henrik Groop (University of Helsinki, Finland)
##SCROLLER_ITEMS_FULL_TITLE##

A changing treatment paradigm in diabetes

July 30, 2016 - Bangkok, Thailand - Richard E. Pratley, MD (Florida Hospital Diabetes Institute, Orlando, FL, USA)

SGLT2 inhibition in diabetic kidney disease

Aug. 24, 2016 - Bangkok, Thailand - Prof. Per-Henrik Groop (University of Helsinki, Finland)
##SCROLLER_ITEMS_FULL_TITLE##

Exciting times in diabetes treatment: new drug class moves beyond glucose reduction

Apr. 23, 2016 - Kuala Lumpur - Naveed Sattar - University of Glasgow, United Kingdom

Heart failure and SGLT2 inhibition: understanding the mechanism for potential benefit

May 21, 2016 - ESC HF 2016, Florence, Italië - Naveed Sattar, MD - Glasgow Universtiy, Glasgow, UK

SGLT2 inhibition and cardiovascular outcomes: lessons from recent clinical trials

May 21, 2016 - ESC HF 2016, Florence, Italy - David Fitchett, MD - University of Toronto, ONT, Canada

New therapies for type 2 diabetes show CV benefit beyond their glucose-lowering effect

Apr. 1, 2016 - VBWG Meeting at ACC 2016, Chicago, IL, USA - Silvio E. Inzucchi, MD - New Haven, CT, USA
##SCROLLER_ITEMS_FULL_TITLE##

The EMPA REG Outcome trial: The challenge for cardiologists in managing T2DM

May 10, 2016 - David Fitchett, MD, University of Toronto, Canad

CV protection by SGLT2 inhibition: Potential mechanisms for benefit

May 10, 2016 - Kuala Lumpur, Malaysia - Prof Hiddo Lambers Heerspink, Groningen, The Netherlands
##SCROLLER_ITEMS_FULL_TITLE##

Recent advances in lowering CV risk with antidiabetic agents

Feb. 12, 2016 - Boston, MA, USA - Prof Stephen Wiviott
##SCROLLER_ITEMS_FULL_TITLE##

CV outcomes with medicines to control glycemia: highlights from recently completed trials

Feb. 2, 2016 - VBWG, Orlando - Darren K. McGuire, MD

The mechanism of SGLT2 inhibition in glucose control

Nov. 24, 2015
##SCROLLER_ITEMS_FULL_TITLE##

Antidiabetic therapy reduces CV mortality and HF outcomes in high-risk patients

Nov. 10, 2015 - AHA 2015, Orlando, FL, USA - Prof. Silvio Inzucchi
##SCROLLER_ITEMS_FULL_TITLE##

SGLT2 inhibitor outcome trials: Future opportunities

Sep. 27, 2015 - London - Dr David Fitchet, Toronto, Canada
##SCROLLER_ITEMS_FULL_TITLE##

SGLT2 inhibition in the management of type 2 diabetes: Potential impact on CVD Risk

Sep. 29, 2015
##SCROLLER_ITEMS_FULL_TITLE##

What is the story about Diabetes & CVD: Rationale for a multifactorial approach

Sep. 29, 2015
##SCROLLER_ITEMS_FULL_TITLE##

The mechanism of SGLT2 inhibition in glucose control

July 24, 2015
##SCROLLER_ITEMS_FULL_TITLE##

Cardiovascular effects of glucose lowering: Safety vs Efficacy

Dec. 12, 2014 - AHA, Chicago VBWG - Dr Silvio E Inzucchi
##SCROLLER_ITEMS_FULL_TITLE##

What do novel diabetes drugs add to CV risk reduction?

Oct. 19, 2014 - Snapshot 2014 - Dr Naveed Sattar
##SCROLLER_ITEMS_FULL_TITLE##

Diabetes therapy and CV outcomes: Risks or benefits?

June 15, 2013 - VBWG San Francisco - Dr Benjamin Scirica

Type of glycemic control is more important than tight glycemic control

May 1, 2017 - ESC HF 2017, Paris
Diabetes worsens risk associated with various CV conditions. Prof. David Fitchett considers the therapeutic options to minimise this CV risk and the increasing role of cardiologists in current optimal management of CV patients with diabetes.

ESC HF 2017 Diabetes worsens risk associated with various CV conditions. Prof. David Fitchett considers the therapeutic options to minimise this CV risk and the increasing role of cardiologists in current optimal management of CV patients with diabetes.

Acute reversible decline in eGFR seen with SGTL2 inhibitor in T2DM patients with or without HF

Apr. 30, 2017 - news
In EMPA-REG OUTCOME, treatment with In EMPA-REG OUTCOME, treatment with empagliflozin first lowered and then stabilised eGFR, while placebo patients showed a decline in the chronic treatment phase.In EMPA-REG OUTCOME, treatment with SGTL2 inhibitor empagliflozin first lowered and then stabilised eGFR, while placebo patients showed a decline in the chronic treatment phase.empagliflozin first lowered and then stabilised eGFR, while placebo patients showed a decline in the chronic treatment phase.

ESC HF 2017 In EMPA-REG OUTCOME, treatment with empagliflozin first lowered and then stabilised eGFR, while placebo patients showed a decline in the chronic treatment phase.

New diabetes treatments with CV benefit: A changing role for the cardiologist

Apr. 19, 2017 - Robert J Chilton, MD (San Antonio, TX, USA)
Dr. Robert J Chilton, MD, argues that new diabetes treatments showing cardiovascular benefit require a different role of the cardiologist.

Dr. Robert J Chilton, MD, argues that new diabetes treatments showing cardiovascular benefit require a different role of the cardiologist. The SGLT2 inhibitor empagliflozin, for example, shows both cardiovascular and renal protection, in addition to lowering glucose.

SGLT-2 inhibitor did not decrease risk of stroke in diabetic patients

Apr. 19, 2017 - Zinman B, et al. - Stroke. 2017

In diabetic patients at high cardiovascular risk, empagliflozin, when compared with placebo, was not associated with either a reduction or an increase in the risk of cerebrovascular events.

SGLT2 inhibitor reduces CV risk factors in patients with and without renal dysfunction

Mar. 23, 2017 - Petrykiv S, et al. - CJASN 2017

SGLT2 inhibitor dapagliflozin consistently reduced blood pressure, body weight and albuminuria, independently of baseline renal function.

Start of first outcome trials empagliflozin in chronic HF

Mar. 23, 2017 - news

The clinical phase III trial EMPEROR HF is initiated and evaluates CV death and hospitalisation for heart failure with empagliflozin in ~7 000 HFrEF and HFpEF patients with or without diabetes

Real world data confirm CV benefits of SGLT-2 inhibitors in diabetic patients

Presented at ACC.17 by Mikhail Kosiborod

Mar. 19, 2017 - news

ACC 2017 In a large real-world study, treatment with SGLT-2 inhibitors versus other glucose-lowering drugs was associated with significant reductions in HF hospitalisation and all-cause death in diabetic patients.

Beneficial effects of SGLT2 inhibitor in diabetic patients with metabolic syndrome

Feb. 21, 2017 - Davies MJ, et al. - Diabetes Metab Syndr Obes, 2017

Canagliflozin had beneficial effects on body weight, BMI, waist circumference, SBP, DBP and HDL-C compared with glimepiride or sitagliptin in T2DM patients with metabolic syndrome.

First T2DM medicine in EU to receive expansion of indication to lower CV death

Feb. 13, 2017 - news

Based on EMPA-REG OUTCOME data, the European Commission has for the first time approved an agent against type 2 diabetes, empagliflozin, to both lower blood glucose and the risk of CV events.

Modifying CV risk by managing diabetes

Nov. 12, 2016 - New Orleans, LA, USA - Jorge Plutzky, MD (Boston, MA, USA)
Dr. Jorge Plutzky, MD, discusses the ability to modulate and modify CV risk with new antidiabetic agents

Dr. Jorge Plutzky, MD, discusses the ability to modulate and modify CV risk with new antidiabetic agents. The use of an SGLT2 inhibitor or a GLP1 agonist should be considered in appropriate patients with diabetes.

FDA approves SGLT2 inhibitor to reduce CV mortality in high-risk adults with type 2 diabetes

Dec. 2, 2016 - news

The SGLT2 inhibitor empagliflozin is the first type 2 diabetes treatment that receives this additional indication based on the CV survival benefit seen the EMPA-REG OUTCOME trial.

What can new glucose-lowering SGLT2-inhibitors add to CV risk management in diabetes?

Aug. 29, 2016 - ESC Rome, Italy - Prof. Silvio E Inzucchi (New Haven, CT, USA)
CV benefit that can be achieved with the new glucose-lowering SGLT2-inhibitor empagliflozin in diabetes

CSI Rome Manon Slob and Shahnam Sharif extensively discuss the results of the EMPA-REG OUTCOME study, the first outcomes trial with an SGLT2 inhibitor, with Prof. Silvio Inzucchi, including what the results may mean for the management of diabetes.

3' education

Type of glycemic control is more important than tight glycemic control

May 1, 2017 - ESC HF 2017, Paris

New diabetes treatments with CV benefit: A changing role for the cardiologist

Apr. 19, 2017 - Robert J Chilton, MD (San Antonio, TX, USA)

Modifying CV risk by managing diabetes

Nov. 12, 2016 - New Orleans, LA, USA - Jorge Plutzky, MD (Boston, MA, USA)

The effect of treatment with DPP-4 inhibition on renal complications in diabetic patients.

Aug. 24, 2016 - Bangkok, Thailand - Prof. Per-Henrik Groop (University of Helsinki, Finland)
##RIGHT_SECTION_ITEMS_FULL_TITLE##

A changing treatment paradigm in diabetes

July 30, 2016 - Bangkok, Thailand - Richard E. Pratley, MD (Florida Hospital Diabetes Institute, Orlando, FL, USA)
##RIGHT_SECTION_ITEMS_FULL_TITLE##

SGLT2 inhibition in diabetic kidney disease

Aug. 24, 2016 - Bangkok, Thailand - Prof. Per-Henrik Groop (University of Helsinki, Finland)

Exciting times in diabetes treatment: new drug class moves beyond glucose reduction

Apr. 23, 2016 - Kuala Lumpur - Naveed Sattar - University of Glasgow, United Kingdom
##RIGHT_SECTION_ITEMS_FULL_TITLE##

New therapies for type 2 diabetes show CV benefit beyond their glucose-lowering effect

Apr. 1, 2016 - VBWG Meeting at ACC 2016, Chicago, IL, USA - Silvio E. Inzucchi, MD - New Haven, CT, USA

The EMPA REG Outcome trial: The challenge for cardiologists in managing T2DM

May 10, 2016 - David Fitchett, MD, University of Toronto, Canad
##RIGHT_SECTION_ITEMS_FULL_TITLE##

CV protection by SGLT2 inhibition: Potential mechanisms for benefit

May 10, 2016 - Kuala Lumpur, Malaysia - Prof Hiddo Lambers Heerspink, Groningen, The Netherlands

Recent advances in lowering CV risk with antidiabetic agents

Feb. 12, 2016 - Boston, MA, USA - Prof Stephen Wiviott
##RIGHT_SECTION_ITEMS_FULL_TITLE##

CV outcomes with medicines to control glycemia: highlights from recently completed trials

Feb. 2, 2016 - VBWG, Orlando - Darren K. McGuire, MD
##RIGHT_SECTION_ITEMS_FULL_TITLE##

Antidiabetic therapy reduces CV mortality and HF outcomes in high-risk patients

Nov. 10, 2015 - AHA 2015, Orlando, FL, USA - Prof. Silvio Inzucchi
##RIGHT_SECTION_ITEMS_FULL_TITLE##

The mechanism of SGLT2 inhibition in glucose control

July 24, 2015
##RIGHT_SECTION_ITEMS_FULL_TITLE##

Cardiovascular effects of glucose lowering: Safety vs Efficacy

Dec. 12, 2014 - AHA, Chicago VBWG - Dr Silvio E Inzucchi
##RIGHT_SECTION_ITEMS_FULL_TITLE##

What do novel diabetes drugs add to CV risk reduction?

Oct. 19, 2014 - Snapshot 2014 - Dr Naveed Sattar
##RIGHT_SECTION_ITEMS_FULL_TITLE##

Diabetes therapy and CV outcomes: Risks or benefits?

June 15, 2013 - VBWG San Francisco - Dr Benjamin Scirica
##RIGHT_SECTION_ITEMS_FULL_TITLE##